Identification of differentially expressed genes and their subpathways in recurrent versus primary bone giant cell tumors

Chen,Shuxin; Li,Chunquan; Wu,Bingli; Zhang,Chunlong; Liu,Cheng; Lin,Xiaoxu; Wu,Xiangqiao; Sun,Lingling; Liu,Chunpeng; Chen,Bo; Zhong,Zhigang; Xu,Liyan; Li,Enmin

doi:10.3892/ijo.2014.2501

Identification of differentially expressed genes and their subpathways in recurrent versus primary bone giant cell tumors

Authors:
- Shuxin Chen
- Chunquan Li
- Bingli Wu
- Chunlong Zhang
- Cheng Liu
- Xiaoxu Lin
- Xiangqiao Wu
- Lingling Sun
- Chunpeng Liu
- Bo Chen
- Zhigang Zhong
- Liyan Xu
- Enmin Li
View Affiliations

Affiliations: Key Laboratory of Molecular Biology in High Cancer Incidence Coastal Chaoshan Area of Guangdong Higher Education Institutes, Medical College of Shantou University, Shantou 515041, P.R. China, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, P.R. China, Department of Orthopedic Surgery, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-Sen University, Shantou 515041, P.R. China
Published online on: June 18, 2014 https://doi.org/10.3892/ijo.2014.2501
Pages: 1133-1142

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Giant cell tumor (GCT) of the bone is a benign but locally aggressive bone neoplasm with a strong tendency to develop local recurrent and metastatic disease. Thus, it provides a useful model system for the identification of biological mechanisms involved in bone tumor progression and metastasis. This study profiled 24 cases of recurrent versus primary bone GCT tissues using QuantiGene 2.0 Multiplex Arrays that included Human p53 80-Plex Panels and Human Stem Cell 80-Plex Panels. A total of 32 differentially expressed genes were identified, including the 20 most upregulated genes and the 12 most downregulated genes in recurrent GCT. The genes identified are related to cell growth, adhesion, apoptosis, signal transduction and bone formation. Furthermore, iSubpathwayMiner analyses were performed to identify significant biological pathway regions (subpathway) associated with this disease. The pathway analysis identified 11 statistically significant enriched subpathways, including pathways in cancer, p53 signaling pathway, osteoclast differentiation pathway and Wnt signaling pathway. Among these subpathways, four genes (IGF1, MDM2, STAT1 and RAC1) were presumed to play an important role in bone GCT recurrence. The differentially expressed MDM2 protein was immunohistochemically confirmed in the recurrent versus primary bone GCT tissues. This study identified differentially expressed genes and their subpathways in recurrent GCT, which may serve as potential biomarkers for the prediction of GCT recurrence.

View Figures

View References

1	Gupta R, Seethalakshmi V, Jambhekar NA, et al: Clinico-pathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India. Ann Diagn Pathol. 12:239–248. 2008. View Article : Google Scholar : PubMed/NCBI
2	Gamberi G, Serra M, Ragazzini P, et al: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 10:351–356. 2003.PubMed/NCBI
3	Szendröi M: Giant cell tumor of bone. J Bone Joint Surg Br. 86:5–12. 2004.PubMed/NCBI
4	Thomas DM and Skubitz KM: Giant cell tumour of bone. Curr Opin Oncol. 21:338–344. 2009. View Article : Google Scholar : PubMed/NCBI
5	Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP and Mendenhall NP: Giant cell tumour of bone. Am J Clin Oncol. 29:96–99. 2006. View Article : Google Scholar : PubMed/NCBI
6	Eckardt JJ and Grogan TJ: Giant cell tumor of bone. Clin Orthop Relat Res. 204:45–58. 1986.PubMed/NCBI
7	Khatri P, Sellamuthu S, Malhotra P, et al: Recent additions and improvements to the Onto-Tools. Nucleic Acids Res. 33:W762–W765. 2005. View Article : Google Scholar : PubMed/NCBI
8	Wang K, Li M and Hakonarson H: Analysing biological pathways in genomewide association studies. Nat Rev Genet. 11:843–854. 2010. View Article : Google Scholar : PubMed/NCBI
9	Becker KG, Barnes KC, Bright TJ and Wang SA: The genetic association database. Nat Genet. 36:431–432. 2004. View Article : Google Scholar
10	Papanastassiou I, Ioannou M, Papagelopoulos PJ, et al: P53 expression as a prognostic marker in giant cell tumor of bone: a pilot study. Orthopedics. 33:3072010.PubMed/NCBI
11	Wülling M, Delling G and Kaiser E: The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol. 34:983–993. 2003.PubMed/NCBI
12	Li C, Li X, Miao Y, et al: SubpathwayMiner: a software package for flexible identification of pathways. Nucleic Acids Res. 37:e1312009. View Article : Google Scholar : PubMed/NCBI
13	Li X, Li C, Shang D, et al: The implications of relationships between human diseases and metabolic subpathways. PLoS One. 6:e211312011. View Article : Google Scholar : PubMed/NCBI
14	Kanehisa M, Goto S, Sato Y, Furumichi M and Tanabe M: KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 40(Database issue): D109–D114. 2012. View Article : Google Scholar : PubMed/NCBI
15	Oda Y, Sakamoto A, Saito T, et al: Secondary malignant giant- cell tumor of bone: molecular abnormalities of p53 and H-ras gene correlated with malignant transformation. Histopathology. 39:6292001. View Article : Google Scholar : PubMed/NCBI
16	Masui F, Ushigome S and Fujii K: Giant cell tumor of bone: a clinicopathologic study of prognostic factors. Pathol Int. 48:7231998. View Article : Google Scholar : PubMed/NCBI
17	Gong L, Liu W, Sun X, et al: Histological and clinical characteristics of malignant giant cell tumor of bone. Virchows Arch. 460:327–334. 2012. View Article : Google Scholar : PubMed/NCBI
18	Boyle WJ, Simonet SW and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
19	Murata A, Fujita T, Kawahara N, Tsuchiya H and Tomita K: Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci. 10:581–588. 2005. View Article : Google Scholar : PubMed/NCBI
20	Guenther R, Krenn V, Morawietz L, et al: Giant cell tumors of bone: molecular profiling and expression analysis of Ephrin A receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol Res Pract. 201:649–663. 2005. View Article : Google Scholar : PubMed/NCBI
21	Skubitz KM, Cheng EY, Clohisy DR, Thompson RC and Skubitz AP: Gene expression in giant cell tumors. J Lab Clin Med. 144:193–200. 2004. View Article : Google Scholar : PubMed/NCBI
22	Kappel CC, Velez-Yanguas MC, Hirschfeld S and Helman LJ: Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res. 54:2803–2807. 1994.PubMed/NCBI
23	Bonjour JP, Schurch MA, Chevalley T, Ammann P and Rizolli R: Protein intake. IGF-1 and osteoporosis. Osteoporosis Int. 7:36–42. 1997. View Article : Google Scholar
24	de Souza PE, Paim JF, Carvalhais JN and Gomez RS: Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor. J Oral Pathol Med. 28:54–58. 1999.PubMed/NCBI
25	Mak IW, Turcotte RE, Popovic S, Singh G and Ghert M: AP-1 as a regulator of MMP-13 in the stromal cell of giant cell tumor of bone. Biochem Res Int. 2011:1641972011.PubMed/NCBI
26	Rao VH, Singh RK, Delimont DC, et al: Interleukin-1beta upregulates MMP-9 expression in stromal cells of human giant cell tumor of bone. J Interferon Cytokine Res. 19:1207–1217. 1999. View Article : Google Scholar : PubMed/NCBI
27	Teti A, Farina AR, Villanova I, et al: Activation of MMP-2 by human GCT23 giant cell tumor cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. Int J Cancer. 77:82–93. 1998. View Article : Google Scholar
28	Mak IW, Seidlitz EP, Cowan RW, et al: Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone. Hum Pathol. 41:1320–1329. 2010. View Article : Google Scholar : PubMed/NCBI
29	Yoon SO, Park SJ, Yun CH and Chung AS: Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 36:128–137. 2003. View Article : Google Scholar : PubMed/NCBI
30	Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
31	Dougall WC, Glaccum M, Charrier K, et al: RANK is essential for osteoclast and lymph node development. Genes Dev. 13:2412–2424. 1999. View Article : Google Scholar : PubMed/NCBI
32	Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
33	Morgan T, Atkins GJ, Trivett MK, et al: Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol. 167:117–128. 2005. View Article : Google Scholar : PubMed/NCBI
34	Geldyyev A, Koleganova N, Piecha G, et al: High expression level of bone degrading proteins as a possible inducer of osteolytic features in pigmented villonodular synovitis. Cancer Lett. 255:275–283. 2007. View Article : Google Scholar
35	Thomas D, Henshaw R, Skubitz K, et al: Denosumab in patients with giant-cell tumor of bone: an open-label, phase 2 study. Lancet Oncol. 11:275–280. 2010. View Article : Google Scholar : PubMed/NCBI
36	Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar
37	Boudný V, Kocák I, Lauerová L and Kovarík J: Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients. Folia Biol. 49:142–146. 2003.PubMed/NCBI
38	Sims NA, Jenkins BJ, Quinn JM, et al: Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest. 113:379–389. 2004. View Article : Google Scholar : PubMed/NCBI
39	Holmen SL, Zylstra CR, Mukherjee A, et al: Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 280:21162–21168. 2005. View Article : Google Scholar : PubMed/NCBI
40	Gaur T, Lengner CJ, Hovhannisyan H, et al: Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem. 280:33132–33140. 2005. View Article : Google Scholar : PubMed/NCBI
41	Goldring SR and Goldring MB: Eating bone or adding it: the Wnt pathway decides. Nat Med. 13:133–134. 2007. View Article : Google Scholar : PubMed/NCBI
42	Matsubayashi S, Nakashima M, Kumagai K, et al: Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis. Pathol Res Pract. 205:626–633. 2009. View Article : Google Scholar : PubMed/NCBI
43	Gamberi G, Benassi MS, Böhling T, et al: Prognostic relevance of C-myc gene expression in giant-ceIl tmnor of bone. J Orthop Res. 16:1–7. 1998. View Article : Google Scholar : PubMed/NCBI
44	Ridley AJ: Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 16:522–529. 2006. View Article : Google Scholar : PubMed/NCBI
45	Stallings-Mann ML, Waldmann J, Zhang Y, Miller E and Gauthier ML: Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med. 4:142ra952012.PubMed/NCBI
46	McAllister SS: Got a light? Illuminating lung cancer. Sci Transl Med. 4:142fs222012.PubMed/NCBI
47	Wang L, Kuang L, Pan X, et al: Isoalvaxant hone inhibits colon cancer cell proliferation, migration and invasion through inactivating Racl and AP-1. Int J Cancer. 127:1220–1229. 2010. View Article : Google Scholar : PubMed/NCBI
48	Fukuda A, Hikita A, Wakeyama H, et al: Regulation of osteoclast apoptosis and motility by small GTPase binding protein Rac1. J Bone Miner Res. 20:2245–2253. 2005. View Article : Google Scholar : PubMed/NCBI